The morphological features of pluronic F127 at various concentrations were investigated and 20% aqueous pluronic F127 solution was chosen for the preparation of biomembrane. The pluronic solution was mixed with appropriate concentration of excipients such as PVA, Povidon S630, PG, Nipagin, Neomycin and Panthenol. The prepared pluronic F127 was thermosensitive, a liquid phase at low temperatures (≤10 °C) but converting into gel at temperatures above 20 °C, and formed stable biomembrane at 37 °C. The neomycin impregnated pluronic membrane suppressed the bacterial growth on agar plate by the sustained release of neomycin. The histological images of skin tissue after applying pluronic gel to burn injured area on rabbit confirmed that the pluronic F127 formulation functioned as a matrix to release drug as well as a biomembrane to protect burn injury. Thus, the formulated pluronic F127 may have a potential for the application of local treatment on burn injury.
The aim of this study was to present primary outcomes of autologous bone marrow mononuclear cell (BMMNC) transplantation to improve neurological sequelae in four children with intracranial hemorrhage (ICH) incidence during the neonatal period. Methods: GMFM88 and modified Ashworth score were used to assess motor function and muscle spasticity before BMMNC transplantation and after transplantation. Brain MRI was performed to evaluate brain morphology before and after BMMNC transplantation. Bone marrow were harvested from anterior iliac crest puncture and BMMNCs were isolated using Ficoll gradient centrifugation. The microbiological testing, cell counting, and hematopoietic stem cell (hHSC CD34+ cell) analysis were performed, following which BMMNCs were infused intrathecally. Results: Improvement in motor function was observed in all patients after transplantation. In addition, muscle spasticity was reduced in all four patients. Conclusion: Autologous BMMNC transplantation may improve motor function and reduce muscle spasticity in children with ICH incidence during the neonatal period.
The rapid creation of vaccinations has increased the risk of vaccine safety. In less than two years, a significant number of COVID-19 vaccines were developed and approved in various countries to control the COVID-19 pandemic. This study was conducted to identify the common adverse events following immunization with mRNA-1273 (Moderna COVID-19) vaccine among adults in 2021. A cross-sectional study using randomized sampling was conducted in Hanoi, Vietnam, with 766 participants. The results show that the prevalence of AEFIs after the 1st dose was significantly lower than after the 2nd dose (41.25% vs. 85.64%, p < 0.05). Local effects, fever, fatigue, and increased pain sensation were the most common side effects encountered in both 1st and 2nd dose. The AEFIs are mostly mild and automatically wore off after one to three days. Therefore, the Moderna COVID-19 vaccine is safe for injection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.